NSEAnalysts/Institutional Investor Meet/Con. Call Updates26 Jun 2026 · 26 Jun 2026, 02:55 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited · WINDLAS
✦ AI Summary
Windlas Biotech Limited has informed the Exchange about a scheduled analyst/institutional investor meeting on July 7, 2026, where the company will discuss publicly available documents and no unpublished price-sensitive information will be shared.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Windlas Biotech Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
WINDLAS_26062026145527_IM_07072026.pdf
View document text
Windlas Biotech Limited
Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199
Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030
CIN-L74899UR2001PLC033407
June 26, 2026
To To
Listing / Compliance Department Listing / Compliance Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street, Mumbai – 400 001 Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
BSE CODE: 543329 NSE SYMBOL: WINDLAS
Dear Sir/ Madam,
Sub: Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and
Disclosure Requirements), Regulations 2015
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, this is to inform you that the officials of our Company will be meeting Investor/Analyst,
the details of which are as under:
Date Particulars Type Time
Tuesday, July 07, 2026 Group of Investors Group (Physical) 5:00 PM onwards
This is to further inform that the Company will be referring to all the publicly available documents for the discussions.
No unpublished price sensitive information (UPSI) will be shared during the meeting.
Please note that changes may happen due to exigencies on the part of Investors/Analysts/Company.
Kindly take the same on record.
Thanking you,
Yours faithfully,
For Windlas Biotech Limited
Ananta Narayan Panda
Company Secretary & Compliance Officer
www.windlas.com